BOSTON (TheStreet) -- This week's Biotech Stock Mailbag is open.

Larry P. asks, "What do you think about

Ampio Pharmaceuticals

(AMPE) - Get Report

and its Australian approval filing for Zertane to treat premature ejaculation."

I always find it a bit bizarre and worrisome when U.S.-based companies like Ampio travel to far-flung corners of the globe seeking drug approvals. If you have a viable and commercially lucrative therapy, why not seek approval first in the big markets of the U.S. or Europe? I suspect the answer is that small, inconsequential drug makers like Ampio venture to Australia more for stock promotion back home than real business interest.

The all-time best example of this scheme was Canadian-based

Generex Biotechnology

seeking approval for its insulin spray in Iraq, Kenya, Bangladesh, Sudan and Yemen -- I kid you not.

Zertane is not unique. It's a new use for the old and generic (i.e. cheap and widely available) painkiller tramadol, formulated into a mint-flavored tablet that dissolves quickly in the mouth. Ampio claims the safest and most efficacious dosages of Zertane for premature ejaculation are 62 mg and 89 mg. Rather random-sounding dosing, except when you understand that standard tramadol can be easily prescribed at a 50 mg dose. Few doctors are going to prescribe Zertane at a higher cost when regular tramadol is already available and much cheaper.

Not only is Zertane nothing special, it's also been previously discarded. Biovail (now owned by Valeant Pharmaceuticals) abandoned phase III clinical trials due to slow patient enrollment and lack of commercial interest in the product, according to regulatory filings. This is how Ampio came to own the rights to Zertane.

Ampio misleads investors when it claims to have conducted a successful phase III study of Zertane involving 604 patients with premature ejaculation. The truth is that Ampio bought rights to the phase III trials run by Biovail, which were terminated well before the planned 2,000-plus patients were enrolled. Ampio combined the two trials together and analyzed results from data available on 604 patients, reaching the conclusion that Zertane significantly delayed ejaculation compared to a placebo.

Ampio's Zertane "study" data were published in August 2011 by

European Urology

, the medical journal of the European Association of Urology.

Three of the four authors of the study work for Ampio, however.

More relevant to the debate over Zertane's ability to receive regulatory approval in Australia or anywhere else is the editorial published in the same issue of

European Urology


Commenting on Ampio's study, Dr. Francois Alexandre Giuliano, a French urologist, concludes: "Overall, tramadol has shown a moderate beneficial effect similar to that of dapoxetine. The tramadol data, however, are from an insufficiently powered combined analysis of two terminated clinical trials. Efficacy and tolerability would have to be further confirmed in more patients and over a longer term."

Now you know why Ampio has run off to Australia seeking Zertane's approval instead of moving forward with filings in the U.S. or Europe where it stands little chance of acceptance. That's the little secret Ampio doesn't want investors to know as it works hard to promotes its stock price.

Props to


(IMGN) - Get Report

CEO Dan Junius for calling me Tuesday to debate his side of the

valuation argument I articulated last Friday

. Junius believes I'm undervaluing the royalty stream that will flow directly to ImmunoGen's bottom line (and cash flow) if/when the breast cancer drug T-DM1 is approved. We agreed to disagree, but I'm glad he reached out to make his views known.

Junius also made the point that ImmunoGen's drug pipeline, outside of T-DM1, deserves more credit. Again, his point is well taken, except my sense speaking to various investors is that ImmunoGen is still very much a T-DM1 story. The pipeline is too early stage and not moving forward fast enough to generate much interest.

ImmunoGen's most advanced internal drug candidate is IMGN1901, only just starting a randomized, controlled phase II study in small cell lung cancer. Results aren't likely to be ready for another 18 months. In terms of partnered drugs,


(SNY) - Get Report

is moving SAR3419 into a phase II study in lymphoma.

Shal60 takes issue with my contention that

Keryx Pharmaceuticals'

(KERX) - Get Report

phosphate binder

Zerenex won't sell well even if approved

because dialysis providers operating under the cost constrictions of a "bundled" Medicare reimbursement system will flock to cheaper, generic phosphate binders.

Writes Shal60: "The bundling you describe relates to services (dialysis) and injection meds (i.e. Procrit, Venofer), but not oral meds, which are gotten through the individual's prescription plan. The providers don't get any reimbursement for oral meds, so generic versus brand name doesn't really affect the dialysis center/provider. However, with generics available, the insurance co/prescription plans will likely cover the generic, but charge a copay for brand drug."

Oral drugs are not included in the Medicare dialysis bundle today but that changes in 2014, when two related events are expected to happen: 1) generic versions of Sanofi/Genzyme's Renagel/Renvela will be launched; and 2) Keryx will launch Zerenex.

From Genzyme's 10-K: "The Medicare Improvements for Patients and Providers Act of 2008, or MIPPA, directs the CMS to establish a bundled payment system to reimburse dialysis providers treating patients with end-stage renal disease, or ESRD. On July 26, 2010, CMS issued a final rule setting forth the dialysis bundled payment system that will begin Jan. 1, 2011. The final rule delays until 2014 the inclusion of ESRD-related oral drugs such as Renagel/Renvela and other oral phosphate binders that do not have an intravenous or injectable equivalent, in the bundled payment system. As a result, Renagel/Renvela will continue to be separately reimbursed by Medicare until 2014."

Once dialysis providers get the chance to lower costs (and boost profits) by switching to generic phosphate binders, Zerenex loses its market.

Frank J. asks, "I've read a number of your articles on


(CVM) - Get Report

. Like most others, I was sucked in to all the hype of their 'breakthrough' drug Multikine. However, the more information I read, the more I'm starting to think it's just a scam to reel in retail investors. With all your history on drug stocks, can you please share your knowledge with all of us on whether this is a blockbuster or a bust? Thank you."

I've lost track of how many times I've counseled biotech investors to run screaming from Cel-Sci, which isn't a drug company as much as it's an efficient cash-transfer mechanism from retail investors to the pockets of Cel-Sci's top executives. President Max de Clara made $645,000 in total compensation last year; CEO Geert Kersten cleared $744,000.

Multikine is a bust. If you're new to the Cel-Sci story, I suggest reading my two-part dismemberment of the Multikine phase II study. Part I covers the

misleading response rate

reported in the study; part II demonstrates the

absurdity of a purported Multikine survival benefit

, as Cel-Sci still claims to this day.

Needless to say, Multikine's ongoing phase III study has zero chance of working -- if it's ever completed at all.

Every few months, Cel-Sci's stock price wakes up from its stupor and moves higher by 20 cents or so, at which point the same motley crew of anonymous message board cretins and shifty stock promoters pour on the stupid by touting the company's supposed blockbuster prospects. And when the pump is done, the stock collapses.

Rinse. Repeat.

I had the following instant conversation chat with an institutional biotech trader this week. The subject:


(VVUS) - Get Report

and the upcoming FDA approval decision for the weight-loss drug Qnexa.

Trader: I think a very good risk of a REMS-like delay.

Me: Possible, but what does the stock do on that?

Trader: Stock dips, then buy the

bleep out of that.

Me: At what point do you turn and short?

Trader: Two hours later? Maybe 10 minutes.

Referring to

Threshold Pharmaceuticals


, @holdiday613 asks, "Any opinions on the TH-302 data?"

The phase II data presented this week on Threshold's pancreatic cancer drug TH-302 were essentially in line with results pre-announced in February: A two-month benefit in progression-free survival from 5.6 months in the TH-302+gemcitabine arm compared to 3.6 months in the gemcitabine-alone arm. It was good see a positive dose response in the trial; better still will be an overall survival benefit, but we need to wait for later in the year for that data to mature.

Relatively few patients in the gemcitabine arm crossed over to take TH-302, which may bode well for the survival analysis. Risks to a survival benefit: Some imbalances between the patient groups in the study, including performance status, which may have skewed the PFS benefit in TH-302's favor. Median overall survival for TH-302 in the 10-month range would be viewed positively.

Threshold shares sold off this week, but that's not unexpected given the huge gains since the initial TH-302 results were announced in February. Threshold was the top-performing biotech stock in the first quarter.

Looking ahead, watch to see if Threshold can convince FDA allow an approval filing based on this phase II study. It's a long shot, so I wouldn't count on it happening, but still, an early filing in pancreatic cancer without the need for a larger phase III trial would definitely send Threshold shares higher.

Threshold is also conducting a phase III study of TH-302 in soft tissue sarcoma, with interim results expected by the end of the year.

If you're interested in a sarcoma drug stock that hasn't yet had a big run, take a look at


(ZIOP) - Get Report

and its drug palifosfamide. Data from a phase III study are expected in the second half of the year.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:






and become a fan on


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.